CompletedPhase 2NCT00679172
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Studying Typhoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emergent BioSolutions
- Principal Investigator
- Stephen Lockhart, DMEmergent BioSolutions
- Intervention
- Dose of 5.0 x 10^9 CFU (Cohort 1)(biological)
- Enrollment
- 187 target
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2008 – 2008
Study locations (3)
- Miami Research Associates, South Miami, Florida, United States
- John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
- Unit of Infectious Diseases, University of Vermont College of Medicine, Burlington, Vermont, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00679172 on ClinicalTrials.govOther trials for Typhoid
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950Induction of Gut Permeability by an Oral VaccineUSDA, Western Human Nutrition Research Center
- ACTIVE NOT RECRUITINGPHASE3NCT03299426Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, MalawiUniversity of Maryland, Baltimore
- ACTIVE NOT RECRUITINGPHASE4NCT03970304CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated AdultsUniversity of Maryland, Baltimore